♦ Haber P, et al. J Pediatr Infect Dis. May 7, 2014, DOI:10.1093/jpids/piu034.

Adverse events after administration of trivalent live-attenuated influenza vaccine (LAIV3) (FluMist) to children ages 2-18 years often involved the vaccine being given to youths for whom it is not recommended, including those with asthma, according to an analysis of reports made to the Vaccine Adverse Event Reporting System (VAERS).

Prelicensure studies and assessment of LAIV3 two years after it was licensed in 2003 did not show any unexpected serious adverse events in those 5-49 years old. To further study the safety of the vaccine in children ages 2-18 years, researchers analyzed VAERS reports from July 1, 2005, to June 30, 2012.

A total of 2,619 reports regarding LAIV3 were filed for children ages 2-18 years, and 197 were considered serious (defined as death, life-threatening illness, hospitalization, prolongation of hospitalization or permanent disability).

Following are some of...

You do not currently have access to this content.